ArticleJournal of gastrointestinal oncology2025
A novel nebulized drug delivery system based on an innovative high-pressure peristaltic pump availably applied to pressurized intraperitoneal aerosol chemotherapy.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of Three Nebulizer Nozzles Used During Pressurized Intraperitoneal Aerosol Chemotherapy Procedures in a Rabbit Model with Peritoneal Surface Malignancies: NOMOS Project.Annals of surgical oncology · 2026Article
- Enhancing laparoscopic visibility: efficient surgical smoke clearance innovatively using nebulization technology.Biomedical engineering online · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management of peritoneal carcinomatosis (PC) remains a significant clinical challenge due to a lack of effective therapies. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been identified as a safe and efficacious treatment for PC. However, despite the observed high potential for PIPAC in treating numerous PC cases, the technology is still limited in China. To address this deficit, we developed a novel nebulized drug delivery system (NDDS) and evaluated it in this study. Methods: The NDDS was developed and was systematically assessed through tests of mechanical properties, granulometric analyses, sprayed distribution tests, and gravimetric analyses; moreover, drug penetration and distribution were examined Results: The NDDS, which included a high-pressure peristaltic pump, demonstrated a pressure initiation time of 5 s and a spray angle of 70°. Nebulization was consistent from the fifth second onward, with a median droplet diameter of 25.0-26.5 µm. The diameters of the sprayed intensive and expanded area were 26.1±1.4 and 48.5±1.0 cm at the vertical distance of 15 cm, and the stress generated was ≤3.790 Pa. Intraluminal drug distribution was extensive but heterogeneity, with 100- to 400-µm drug penetration depth (PD), and the optimal drug PD was observed in locations directly opposite to or adjacent surrounding the nozzle. Conclusions: The developed NDDS demonstrated promising mechanical properties, effective granulometric characteristics, extensive spray coverage, and satisfactory drug penetration and distribution. It offers a practicable solution for the application of PIPAC and will hopefully improve the current dilemma in PC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.